0001209191-23-058404.txt : 20231212
0001209191-23-058404.hdr.sgml : 20231212
20231212193027
ACCESSION NUMBER: 0001209191-23-058404
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231211
FILED AS OF DATE: 20231212
DATE AS OF CHANGE: 20231212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wagner Paul A.
CENTRAL INDEX KEY: 0001612842
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38052
FILM NUMBER: 231482587
MAIL ADDRESS:
STREET 1: C/O PFENEX INC.
STREET 2: 10790 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Forte Biosciences, Inc.
CENTRAL INDEX KEY: 0001419041
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261243872
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (310) 618-6994
MAIL ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
FORMER COMPANY:
FORMER CONFORMED NAME: Tocagen Inc
DATE OF NAME CHANGE: 20071120
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-11
0
0001419041
Forte Biosciences, Inc.
FBRX
0001612842
Wagner Paul A.
C/O FORTE BIOSCIENCES, INC.
3060 PEGASUS PARK DR., BLDG 6
DALLAS
TX
75247
1
1
0
0
See Remarks
0
Common Stock
2023-12-11
4
P
0
25000
0.6475
A
1787940
D
Common Stock
2023-12-12
4
P
0
4776
0.6466
A
1792716
D
Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $0.6199 to $0.65 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average share price of an aggregate total of 4,776 shares purchased in the price range of $0.639 to $0.65 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
CEO, Secretary and Chair of the Board
/s/ Paul A. Wagner, Ph.D.
2023-12-12